Temple University School of Medicine, Allegheny General Hospital, Pittsburgh, PA, USA.
Eur J Vasc Endovasc Surg. 2013 Oct;46(4):480-7. doi: 10.1016/j.ejvs.2013.07.012. Epub 2013 Aug 21.
Examine the effectiveness of an advanced pneumatic compression device (APCD) in reducing limb volume (LV), and to evaluate clinician and patient-reported outcomes.
Device registry study.
Data were collected prospectively for 196 lower extremity lymphedema patients prescribed an APCD. Baseline and post-treatment LVs were calculated and clinical outcomes (skin changes, pain, and function) were assessed. Patient-reported outcomes and satisfaction utilizing a pre- and post-treatment survey were also evaluated.
90% of APCD-treated patients experienced a significant reduction in LV with 35% enjoying a reduction >10%. Mean LV reduction was 1,150 mL or 8% (p < .0001). Greater baseline LV and BMI were strong predictors of LV reduction (p < .0001). Clinician assessment indicated that the majority of patients experienced improvement in skin fibrosis and function. Patient-reported outcomes showed a significant increase in ability to control lymphedema through APCD treatment, with an increase in function and a reduction in the interference of pain. 66% were "very satisfied" with the APCD treatment.
APCD use is associated with consistent reductions in LV, with favorable patient-reported outcomes. Results demonstrate that reduction in LV and pain, combined with functional improvement and patient satisfaction can be achieved, providing tangible benefit for lower extremity patients.
研究一种先进的气动压缩装置（APCD）在减少肢体体积（LV）方面的有效性，并评估临床医生和患者报告的结果。
装置注册研究。
前瞻性收集了 196 例下肢淋巴水肿患者使用 APCD 的数据。计算了基线和治疗后的 LV，并评估了临床结果（皮肤变化、疼痛和功能）。还利用治疗前后的调查评估了患者报告的结果和满意度。
90%的 APCD 治疗患者的 LV 显著减少，35%的患者减少>10%。平均 LV 减少 1150 毫升或 8%（p<0.0001）。更大的基线 LV 和 BMI 是 LV 减少的强预测因素（p<0.0001）。临床医生评估表明，大多数患者的皮肤纤维化和功能均有改善。患者报告的结果表明，通过 APCD 治疗能够更好地控制淋巴水肿，功能增加，疼痛干扰减少。66%的患者对 APCD 治疗“非常满意”。
APCD 的使用与 LV 的持续减少相关，患者报告的结果良好。结果表明，可以实现 LV 和疼痛的减少，以及功能的改善和患者的满意度，为下肢患者带来切实的益处。
